PANACUR 10% Suspension (Brazil)

Merck Animal Health

Revision date : 2012-03-02

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS09
Health risk rating 1
Safety risk rating 1
Environmental risk rating 5

General Information

Revision date

2012-03-02

Product name

PANACUR 10% Suspension (Brazil)

Emergency telephone

(908) 423-6000 (24/7/365) English Only

Icons in SDS

GHS09

Company Information

company name

Merck Animal Health

Section 2

SECTION 2: Hazards identification

OSHA EMERGENCY OVERVIEW Liquid, Suspension White Odor unknown Possible risk of harm to the unborn child. May cause allergic reactions in susceptible individuals. May cause effects to: gastrointestinal tract central nervous system liver bone marrow blood kidney immune system fetus Very toxic to aquatic life with long lasting effects.

Potential health effects

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s). The active ingredient fenbendazole is a benzimidazole carbamate anthelmintic that is structurally related to mebendazole. Therapeutic use of mebendazole, a substance of the same chemical class as fenbendazole, has been reported to cause gastrointestinal disturbances (transient abdominal pain), diarrhea, headache, and dizziness. Frequent effects reported after treatment with high-doses of mebendazole have included allergic reactions (fever and skin reactions), raised liver enzyme values, alopecia, bone marrow depression, reduced leucocyte count and raised serum-transaminase values. A number of oral subchronic and chronic animal studies have been conducted with fenbendazole and have demonstrated that the liver is the main target tissue. In addition, stomach, kidneys, blood, immune system, and central nervous system are also affected by treatment with fenbendazole. Devlopmental effects have been reported in rabbits following treatment with fenbendazole. LISTED CARCINOGENS No carcinogens or potential carcinogens listed by

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.